Analysts Expect Opko Health Inc. (OPK) Will Post Quarterly Sales of $307.44 Million
Wall Street analysts expect that Opko Health Inc. (NASDAQ:OPK) will announce sales of $307.44 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Opko Health’s earnings. The lowest sales estimate is $296.51 million and the highest is $325.20 million. Opko Health reported sales of $275.50 million during the same quarter last year, which would suggest a positive year over year growth rate of 11.6%. The business is scheduled to report its next earnings report on Wednesday, March 7th.
On average, analysts expect that Opko Health will report full year sales of $307.44 million for the current fiscal year, with estimates ranging from $1.17 billion to $1.20 billion. For the next financial year, analysts forecast that the firm will report sales of $1.29 billion per share, with estimates ranging from $1.26 billion to $1.34 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Opko Health.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The company had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. During the same quarter last year, the company posted ($0.03) EPS. Opko Health’s revenue was down 11.6% on a year-over-year basis.
Shares of Opko Health (OPK) opened at $4.92 on Wednesday. Opko Health has a 52-week low of $4.50 and a 52-week high of $12.03. The company has a market capitalization of $2,750.00, a price-to-earnings ratio of -25.89 and a beta of 1.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66.
In other news, major shareholder Opko Health, Inc. acquired 655,738 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was acquired at an average cost of $3.05 per share, for a total transaction of $2,000,000.90. Following the completion of the acquisition, the insider now owns 6,678,752 shares in the company, valued at $20,370,193.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 40.19% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of the business. Blair William & Co. IL acquired a new stake in shares of Opko Health in the second quarter valued at about $112,000. Crossmark Global Holdings Inc. acquired a new stake in shares of Opko Health in the third quarter valued at about $118,000. Engineers Gate Manager LP acquired a new stake in shares of Opko Health in the second quarter valued at about $117,000. Abbot Financial Management Inc. acquired a new stake in shares of Opko Health in the second quarter valued at about $129,000. Finally, BB&T Securities LLC grew its position in shares of Opko Health by 7.6% in the second quarter. BB&T Securities LLC now owns 20,600 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 1,460 shares during the last quarter. 22.90% of the stock is currently owned by hedge funds and other institutional investors.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.